Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24weeks
Just $1.99 per week for the first 24weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

Cannabis Professional’s daily roundup of industry news. View archive here.

MedMen’s Adam Bierman stepping down as CEO

MedMen Enterprises Inc.’s Adam Bierman is stepping down as CEO, the U.S. cannabis retailer announced Friday. As part of the move, Mr. Bierman will surrender all of his Class A supervoting shares, which had previously given him significant personal control over the company. Co-founder Andrew Mondlin has also agreed to give up his super voting shares, the company said.

The shares will be replaced by subordinate voting shares, giving Mr. Bierman and Mr. Mondlin control of 4.8 and 4.9 per cent of company votes respectively. MedMen will compensate them for the loss of control, although it did not say how much the payout would be worth. MedMen has named its chief operating officer Ryan Lissack interim CEO.

Story continues below advertisement

Mr. Bierman’s departure comes as the company continues to burn cash and struggle to pay its bills. In October, the company pulled the plug on a US$682 million takeover of PharmaCann; a month later, it announced that it was laying off 190 employees as part of restructuring effort to get costs under control.

This is just the latest in a string of CEO departures from pot companies. This week alone saw Torsten Kuenzlen step down as CEO of Sundial Growers Inc., and Michael Nashat step down as CEO of TerrAscend Corp. Earlier in the month, Navdeep Dhaliwal departed as CEO of The Supreme Cannabis Company.

– Mark Rendell

MediPharm’s Australian subsidiary receives import licence

An Australian subsidiary of MediPharm Labs Corp. has received a licence from the Australian government to import Schedule 4 drugs, including cannabis, into the country. The receipt of the licence is a step towards MediPharm being able to ship medical cannabis to Australia, the company said Friday. However, several more steps need to be taken before this can happen. MediPharm’s Australian subsidiary still needs to get Good Manufacturing Practices certification. Any shipment would also require import and export permits from the Canadian and Australian governments respectively.

- Mark Rendell

Recently, around the industry:

Related topics

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies